MEDLINE Journals

    Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.

    Waters GS, Ahmad M, Katsarkas A, et al. 
    Ear Hear 1991 Apr; 12(2) :91-102.

    Ototoxicity associated with administration of cisplatin was assessed in four groups of patients suffering from advanced ovarian carcinoma. The purpose was to determine the influence of dosage, schedule of administration, and long-term treatment on pure-tone thresholds and other auditory parameters. One hundred and forty-five serial audiograms were obtained in 60 patients and compared with baseline audiograms. The treatment protocol consisted of two different dosages (low--50 mg/m2 and high--100 mg/m2) and three different schedules of administration (short--6 months, extended--12 months, and treatment in blocks--intervening months in which cisplatin was withheld). Using a conservative definition of auditory toxicity and statistical analyses of pure-tone threshold differences between groups, the results indicated that the low dose-short treatment regimens with either monthly administration of cisplatin, or administration in blocks, were the least ototoxic. Ototoxicity was found to increase with increasing cumulative dosages. Hearing loss was primarily in the high frequencies. The most severe ototoxic effects, which include tinnitus and hearing loss in the speech frequency range, were associated with the administration of high dosages over a short period of time. Individual variability in susceptibility to ototoxicity necessitates systematic audiometric monitoring throughout therapy.

    Analysis of Variance
    Auditory Threshold
    Dose-Response Relationship, Drug
    Drug Administration Schedule
    Hearing Disorders
    Hearing Loss
    Hearing Loss, Bilateral
    Hearing Loss, High-Frequency
    Middle Aged
    Ovarian Neoplasms
    Retrospective Studies
    Time Factors


    Pub Type(s)
    Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't
    PubMed ID


    Content Manager
    Related Content

    Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration.

    Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.

    Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.

    Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.

    The importance of high-tone audiometry in monitoring for ototoxicity.

    Relationship between cisplatin administration and the development of ototoxicity.

    Factors influencing ototoxicity in ovarian cancer patients treated with Cis-platinum based chemotherapy.

    Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients.